Celgene Wants Sun Pharma's Revlimid Generic Blocked
By Dani Kass ( April 17, 2019, 6:16 PM EDT) -- Celgene has asked a New Jersey federal court to stop Sun Pharma from moving forward with its generic version of the blockbuster cancer medication Revlimid until three patents expire....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.